Holen Sie sich die Stockscreener-App
109.64
1.17%
-1.295
Vorhandelsmarkt:
109.26
-0.375
-0.34%
Schlusskurs vom Vortag:
$110.93
Offen:
$112.5
24-Stunden-Volumen:
2.37M
Relative Volume:
2.02
Marktkapitalisierung:
$8.54B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-159.39M
KGV:
-30.97
EPS:
-3.5401
Netto-Cashflow:
$-105.22M
1W Leistung:
-12.77%
1M Leistung:
+11.15%
6M Leistung:
+1,260%
1J Leistung:
+1,133%
1-Tages-Spanne:
$107.06
$112.56
1-Wochen-Bereich:
$107.06
$126.97
52-Wochen-Spanne:
$4.77
$130.25
Abivax Adr Stock (ABVX) Company Profile
Vergleichen Sie ABVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
109.64 | 8.64B | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-06 | Eingeleitet | Wolfe Research | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-07-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-12-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | Laidlaw | Buy |
| 2024-05-20 | Eingeleitet | BTIG Research | Buy |
| 2024-04-29 | Eingeleitet | Guggenheim | Buy |
| 2024-04-29 | Eingeleitet | Piper Sandler | Overweight |
| 2023-11-14 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Abivax Adr Aktie (ABVX) Neueste Nachrichten
Quadrature Capital Ltd Acquires Shares of 19,367 Abivax SA Sponsored ADR $ABVX - MarketBeat
Investors in cash trouble should check out Abivax ADR (ABVX) - Setenews
There is no doubt that Abivax ADR (ABVX) ticks all the boxes. - Setenews
Abivax SA Sponsored ADR (ABVX) Receives a New Rating from Truist Financial - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Rating of “Buy” from Analysts - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Abivax (NASDAQ:ABVX) Sees Large Volume IncreaseHere's Why - MarketBeat
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025 - ts2.tech
Is Abivax ADR (ABVX) positioned for future growth? - Setenews
Nothing is Better Than Kyivstar Group Ltd (KYIV) stock at the moment - Setenews
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 12-Month HighStill a Buy? - MarketBeat
Abivax (NASDAQ:ABVX) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know - MSN
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year? - sharewise.com
A new trading data show Abivax ADR (ABVX) is showing positive returns. - Setenews
Akebia Therapeutics (AKBA) Receives a Buy from BTIG - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 52-Week HighShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR) - The Globe and Mail
Get in on Abivax ADR’s (ABVX) buy-in window today! - Setenews
Wall Street analysts’ outlook for Zevia PBC (ZVIA) - Setenews
Positive Outlook for Abivax SA: Obefazimod’s Potential in Crohn’s Disease Drives Buy Rating - TipRanks
What is Abivax ADR (ABVX) Stock Return on Shareholders’ Capital? - Setenews
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Decrease in Short Interest - MarketBeat
ETFs Investing in Abivax SA Sponsored ADR Stocks - TradingView
Leerink Partnrs Analysts Raise Earnings Estimates for Abivax - Defense World
Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Abivax Shares Surge After Strong Phase 3 Results in Ulcerative Colitis Study - MSN
Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease - Investor's Business Daily
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data - GlobeNewswire Inc.
FY2025 EPS Estimates for Abivax Boosted by Lifesci Capital - Defense World
Abivax SA Reports Financial Results and Strategic Advances - MSN
Abivax Reports Increased Losses but Secures Major Funding in H1 2025 - msn.com
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Up 42.1% in August - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Increase in Short Interest - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $95.14 Consensus PT from Brokerages - MarketBeat
Abivax (NASDAQ:ABVX) Shares Gap Down – What’s Next? - Defense World
Octagon Capital Advisors LP Makes New $7.69 Million Investment in Abivax SA Sponsored ADR $ABVX - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Down 38.0% in August - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Buy” by Brokerages - Defense World
Market Movers: Robinhood, AppLovin Surge into S&P 500 Amidst Crucial Earnings Season - FinancialContent
Abivax SA Sponsored ADR $ABVX Stock Position Increased by ADAR1 Capital Management LLC - MarketBeat
Paloma Partners Management Co Purchases Shares of 38,449 Abivax SA Sponsored ADR $ABVX - MarketBeat
Finanzdaten der Abivax Adr-Aktie (ABVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):